Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Investigational Tirzepatide Doses in Participants With Type 2 Diabetes and Obesity

NCT06037252 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06037252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06037252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Investigational Tirzepatide Doses in Participants With Type 2 Diabetes and Obesity
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 21, 2023
Completion date
October 31, 2026
Enrollment
414 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, type 2 diabetes